Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Circulating tumor cells, tumor-derived extracellular vesicles and plasma cytokeratins in castration-resistant prostate cancer patients.

Nanou A, Coumans FAW, van Dalum G, Zeune LL, Dolling D, Onstenk W, Crespo M, Fontes MS, Rescigno P, Fowler G, Flohr P, Brune C, Sleijfer S, de Bono JS, Terstappen LWMM.

Oncotarget. 2018 Apr 10;9(27):19283-19293. doi: 10.18632/oncotarget.25019. eCollection 2018 Apr 10.

2.

Scanning Electron Microscopy of Circulating Tumor Cells and Tumor-Derived Extracellular Vesicles.

Nanou A, Crespo M, Flohr P, De Bono JS, Terstappen LWMM.

Cancers (Basel). 2018 Oct 31;10(11). pii: E416. doi: 10.3390/cancers10110416.

3.

Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer.

Bitting RL, Healy P, Halabi S, George DJ, Goodin M, Armstrong AJ.

Urol Oncol. 2015 Mar;33(3):110.e1-9. doi: 10.1016/j.urolonc.2014.09.002. Epub 2015 Jan 13.

PMID:
25595577
4.

Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer.

Goldkorn A, Ely B, Quinn DI, Tangen CM, Fink LM, Xu T, Twardowski P, Van Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP 3rd, Datar RH, Garzotto M, Mack PC, Lara P Jr, Higano CS, Hussain M, Thompson IM Jr, Cote RJ, Vogelzang NJ.

J Clin Oncol. 2014 Apr 10;32(11):1136-42. doi: 10.1200/JCO.2013.51.7417. Epub 2014 Mar 10.

5.

Combination of circulating tumor cell enumeration and tumor marker detection in predicting prognosis and treatment effect in metastatic castration-resistant prostate cancer.

Chang K, Kong YY, Dai B, Ye DW, Qu YY, Wang Y, Jia ZW, Li GX.

Oncotarget. 2015 Dec 8;6(39):41825-36. doi: 10.18632/oncotarget.6167.

6.

Circulating tumor cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer.

De Laere B, Oeyen S, Van Oyen P, Ghysel C, Ampe J, Ost P, Demey W, Hoekx L, Schrijvers D, Brouwers B, Lybaert W, Everaert E, Van Kerckhove P, De Maeseneer D, Strijbos M, Bols A, Fransis K, Beije N, de Kruijff I, van Dam V, Brouwer A, van Dam PJ, Van den Eynden G, Rutten A, Sleijfer S, Vandebroek J, Van Laere S, Dirix L.

Prostate. 2018 May;78(6):435-445. doi: 10.1002/pros.23488. Epub 2018 Feb 12.

PMID:
29431193
7.

Circulating tumor cells in patients with castration-resistant prostate cancer baseline values and correlation with prognostic factors.

Goodman OB Jr, Fink LM, Symanowski JT, Wong B, Grobaski B, Pomerantz D, Ma Y, Ward DC, Vogelzang NJ.

Cancer Epidemiol Biomarkers Prev. 2009 Jun;18(6):1904-13. doi: 10.1158/1055-9965.EPI-08-1173.

9.

Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer.

Lorente D, Olmos D, Mateo J, Bianchini D, Seed G, Fleisher M, Danila DC, Flohr P, Crespo M, Figueiredo I, Miranda S, Baeten K, Molina A, Kheoh T, McCormack R, Terstappen LW, Scher HI, de Bono JS.

Eur Urol. 2016 Dec;70(6):985-992. doi: 10.1016/j.eururo.2016.05.023. Epub 2016 Jun 9.

10.

Prognostic association of plasma cell-free DNA-based androgen receptor amplification and circulating tumor cells in pre-chemotherapy metastatic castration-resistant prostate cancer patients.

Kohli M, Li J, Du M, Hillman DW, Dehm SM, Tan W, Carlson R, Campion MB, Wang L, Wang L, Zhang H, Zhang P, Kilari D, Huang CC, Wang L.

Prostate Cancer Prostatic Dis. 2018 Sep;21(3):411-418. doi: 10.1038/s41391-018-0043-z. Epub 2018 Jun 1.

PMID:
29858592
11.

Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer.

de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LW, Pienta KJ, Raghavan D.

Clin Cancer Res. 2008 Oct 1;14(19):6302-9. doi: 10.1158/1078-0432.CCR-08-0872. Erratum in: Clin Cancer Res. 2009 Feb 15;15(4):1506.

12.

Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancer.

Goodman OB Jr, Symanowski JT, Loudyi A, Fink LM, Ward DC, Vogelzang NJ.

Clin Genitourin Cancer. 2011 Sep;9(1):31-8. doi: 10.1016/j.clgc.2011.04.001. Epub 2011 Jun 25.

PMID:
21705286
13.

Circulating prostate tumor cells detected by reverse transcription-PCR in men with localized or castration-refractory prostate cancer: concordance with CellSearch assay and association with bone metastases and with survival.

Helo P, Cronin AM, Danila DC, Wenske S, Gonzalez-Espinoza R, Anand A, Koscuiszka M, Väänänen RM, Pettersson K, Chun FK, Steuber T, Huland H, Guillonneau BD, Eastham JA, Scardino PT, Fleisher M, Scher HI, Lilja H.

Clin Chem. 2009 Apr;55(4):765-73. doi: 10.1373/clinchem.2008.117952. Epub 2009 Feb 20.

14.

Limited prognostic value of preoperative circulating tumor cells for early biochemical recurrence in patients with localized prostate cancer.

Meyer CP, Pantel K, Tennstedt P, Stroelin P, Schlomm T, Heinzer H, Riethdorf S, Steuber T.

Urol Oncol. 2016 May;34(5):235.e11-6. doi: 10.1016/j.urolonc.2015.12.003. Epub 2016 Jan 12.

PMID:
26795608
15.
16.

Molecular profiling of peripheral blood is associated with circulating tumor cells content and poor survival in metastatic castration-resistant prostate cancer.

Marín-Aguilera M, Reig Ò, Lozano JJ, Jiménez N, García-Recio S, Erill N, Gaba L, Tagliapietra A, Ortega V, Carrera G, Colomer A, Gascón P, Mellado B.

Oncotarget. 2015 Apr 30;6(12):10604-16. Erratum in: Oncotarget. 2017 Apr 18;8(16):27673.

17.

Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial.

Goldkorn A, Ely B, Tangen CM, Tai YC, Xu T, Li H, Twardowski P, Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP 3rd, Garzotto M, Mack PC, Lara P Jr, Higano CS, Hussain M, Vogelzang NJ, Thompson IM Jr, Cote RJ, Quinn DI.

Int J Cancer. 2015 Apr 15;136(8):1856-62. doi: 10.1002/ijc.29212. Epub 2014 Oct 8.

18.

Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience.

Olmos D, Arkenau HT, Ang JE, Ledaki I, Attard G, Carden CP, Reid AH, A'Hern R, Fong PC, Oomen NB, Molife R, Dearnaley D, Parker C, Terstappen LW, de Bono JS.

Ann Oncol. 2009 Jan;20(1):27-33. doi: 10.1093/annonc/mdn544. Epub 2008 Aug 11.

PMID:
18695026
19.

mRNA expression profiles in circulating tumor cells of metastatic colorectal cancer patients.

Mostert B, Sieuwerts AM, Bolt-de Vries J, Kraan J, Lalmahomed Z, van Galen A, van der Spoel P, de Weerd V, Ramírez-Moreno R, Smid M, Verhoef C, IJzermans JN, Gratama JW, Sleijfer S, Foekens JA, Martens JW.

Mol Oncol. 2015 Apr;9(4):920-32. doi: 10.1016/j.molonc.2015.01.001. Epub 2015 Jan 21.

20.

Serum chromogranin-A-based prognosis in metastatic castration-resistant prostate cancer.

Giridhar KV, Sanhueza C, Hillman DW, Alkhateeb H, Carlson R, Tan W, Costello BA, Quevedo F, Pagliaro L, Kohli M.

Prostate Cancer Prostatic Dis. 2018 Sep;21(3):431-437. doi: 10.1038/s41391-018-0046-9. Epub 2018 Jun 1.

PMID:
29858590

Supplemental Content

Support Center